Non-COVID portfolio steps up: Pfizer outpaces consensus and hikes guidance
Pfizer Inc. PFE on Tuesday reported third-quarter sales of $16.58 billion, beating the consensus of $15.87 billion. The ...
Model output · Signal date 2026-11-06
Pfizer Inc (PFE) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
9.0%
Spearman, 357 dates
Market Cap
$167.51B
large-cap · #9 of 60 peers
Summary
Pfizer Inc (PFE) stock forecast summary
Our AI scores Pfizer Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Pfizer Inc is a large-cap company with a market capitalization of $167.51B. It ranks number 9 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its Dividend Yield of 5.85% is the highest of the 10 peers that report one.
For PFE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 9.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 25.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PFE included.
Price
PFE price chart and AI forecast
Cross-section · 2026-11-06
How PFE ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-27
Pfizer Inc (PFE) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | PFE | Rank |
|---|---|---|
| Market Cap | $167.51B | 9/60 |
| P/E Ratio | 37.20x | 16/32 |
| P/B Ratio | 1.88x | 41/42 |
| Dividend Yield | 5.85% | 1/10 |
| EPS | $0.79 | – |
| Book Value/Share | $15.62 | – |
| Revenue/Share | $11.16 | – |
| FCF/Share | $2.07 | – |
Profitability & Margins
| Metric | PFE | Rank |
|---|---|---|
| ROE | 4.5% | 22/38 |
| ROA | 2.0% | 21/42 |
| Gross Margin | 73.4% | 23/36 |
| Net Margin | 6.3% | 18/35 |
| EBT Margin | 6.7% | 25/46 |
| Tax Rate | 4.4% | – |
Financial Health
| Metric | PFE | Rank |
|---|---|---|
| Current Ratio | 1.42x | 44/58 |
| Quick Ratio | 1.10x | 30/43 |
| D/E Ratio | 1.29x | 22/47 |
| Financial Leverage | 2.30x | 20/47 |
| Working Capital | $13.28B | 3/58 |
Cash Flow
| Metric | PFE | Rank |
|---|---|---|
| Operating Cash Flow | $14.17B | 11/59 |
| Free Cash Flow | $11.79B | 9/50 |
| Capital Spending | -$2.39B | 43/50 |
| OCF Growth YoY | 8.4% | 16/34 |
| FCF Growth YoY | 13.6% | 10/32 |
| FCF/Sales | 18.5% | 21/42 |
| CapEx/Sales | 3.8% | 19/42 |
Operational Efficiency
| Metric | PFE | Rank |
|---|---|---|
| Asset Turnover | 0.31x | 33/39 |
| Receivables Turnover | 4.5x | 24/36 |
| Inventory Turnover | 1.7x | 18/35 |
| Fixed Assets Turnover | 3.3x | 31/41 |
| Days Sales Outstanding | 81 days | 13/36 |
| Days Inventory | 216 days | 18/35 |
| Payables Period | 88 days | 18/24 |
| Cash Conversion Cycle | 210 days | 11/22 |
Income Statement
| Metric | PFE | Rank |
|---|---|---|
| Total Revenue | $63.62B | 9/46 |
| Net Income | $4.03B | 11/46 |
| R&D Expense | $11.52B | 9/58 |
| SG&A Expense | $13.81B | 8/40 |
| Cost of Goods Sold | $16.94B | 11/37 |
Dividend & Shareholder Information
| Metric | PFE | Rank |
|---|---|---|
| Dividends Per Share | $1.72 | – |
| Payout Ratio | 217.7% | 2/10 |
| Shares Outstanding | 5700M | – |
| Net Income Growth | -59.0% | 18/23 |
| EPS Growth | -55.1% | 20/24 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $45.01B | 22.0% of assets |
| Cash & Short-term Investments | $1.82B | 0.9% of assets |
| Accounts Receivable | $14.19B | 6.9% of assets |
| Inventory | $10.02B | 4.9% of assets |
| Total Liabilities | $115.24B | 56.3% of assets |
| Short-term Debt | $27.66B | 13.5% of assets |
Quarterly Financial Reports
PFE quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Pfizer Inc (PFE) industry peers
Companies classified under the same SEC industry code as Pfizer Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PFE Pfizer Inc | $167.51B | |
| LLY Eli Lilly & Co | $1.28T | |
| JNJ Johnson & Johnson | $664.95B | |
| ABBV Abbvie Inc. | $514.78B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $288.97B | |
| ABT Abbott Laboratories | $191.15B | |
| NVO Novo Nordisk A S | $179.14B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137.50B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $101.70B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $34.50B | |
| ZTS Zoetis Inc. | $33.93B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $26.45B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.89B | |
| ASND Ascendis Pharma A/S | $16.86B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| ELAN Elanco Animal Health Inc | $12.86B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $10.85B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | |
| TGTX Tg Therapeutics, Inc. | $9.20B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.22B | |
| CORT Corcept Therapeutics Inc | $7.87B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| ALKS Alkermes Plc. | $7.70B | |
| ABVX Abivax S.A. | $7.50B | |
| CYTK Cytokinetics Inc | $7.46B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $6.94B | |
| AXSM Axsome Therapeutics, Inc. | $6.93B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.43B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | |
| BLTE Belite Bio, Inc | $6.07B | |
| LGND Ligand Pharmaceuticals Inc | $5.98B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.64B | |
| ERAS Erasca, Inc. | $4.64B | |
| TVTX Travere Therapeutics, Inc. | $4.44B | |
| LEGN Legend Biotech Corp | $4.17B |
Where PFE sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Pfizer Inc (PFE) stock news
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than ...
Amazon, Pfizer, Eaton and a financial stock on CNBC’s ‘Final Trades’
On CNBC’s “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Amazon.com, ...
FAQ
Pfizer Inc (PFE) stock forecast FAQ
What is the Pfizer Inc (PFE) stock forecast?
Our AI scores Pfizer Inc every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Pfizer Inc stock predictions?
For PFE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 9.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 25.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Pfizer Inc forecasts updated?
Pfizer Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Pfizer Inc's industry peers?
60 issuers in our coverage, PFE included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.